Division of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Department of Biomedical Engineering, Duke University, Durham, NC, USA.
Mol Genet Metab. 2021 Nov;134(3):223-234. doi: 10.1016/j.ymgme.2021.10.002. Epub 2021 Oct 9.
Early recognized manifestations of GSD III include hypoglycemia, hepatomegaly, and elevated liver enzymes. Motor symptoms such as fatigue, muscle weakness, functional impairments, and muscle wasting are typically reported in the 3rd to 4th decade of life.
In this study, we investigated the early musculoskeletal findings in children with GSD IIIa, compared to a cohort of adults with GSD IIIa.
We utilized a comprehensive number of physical therapy outcome measures to cross-sectionally assess strength and gross motor function including the modified Medical Research Council (mMRC) scale, grip and lateral/key pinch, Gross Motor Function Measure (GMFM), Gait, Stairs, Gowers, Chair (GSGC) test, 6 Minute Walk Test (6MWT), and Bruininks-Oseretsky Test of Motor Proficiency Ed. 2 (BOT-2). We also assessed laboratory biomarkers (AST, ALT, CK and urine Glc4) and conducted whole-body magnetic resonance imaging (WBMRI) to evaluate for proton density fat fraction (PDFF) in children with GSD IIIa. Nerve Conduction Studies and Electromyography results were analyzed where available and a thorough literature review was conducted.
There were a total of 22 individuals with GSD IIIa evaluated in our study, 17 pediatric patients and 5 adult patients. These pediatric patients demonstrated weakness on manual muscle testing, decreased grip and lateral/key pinch strength, and decreased functional ability compared to non-disease peers on the GMFM, 6MWT, BOT-2, and GSGC. Additionally, all laboratory biomarkers analyzed and PDFF obtained from WBMRI were increased in comparison to non-diseased peers. In comparison to the pediatric cohort, adults demonstrated worse overall performance on functional assessments demonstrating the expected progression of disease phenotype with age.
These results demonstrate the presence of early musculoskeletal involvement in children with GSD IIIa, most evident on physical therapy assessments, in addition to the more commonly reported hepatic symptoms. Muscular weakness in both children and adults was most significant in proximal and trunk musculature, and intrinsic musculature of the hands. These findings indicate the importance of early assessment of patients with GSD IIIa for detection of muscular weakness and development of treatment approaches that target both the liver and muscle.
GSD III 的早期表现包括低血糖、肝肿大和肝酶升高。疲劳、肌肉无力、功能障碍和肌肉消耗等运动症状通常在生命的第 3 至 4 个十年报告。
本研究旨在比较 GSD IIIa 患儿与 GSD IIIa 成人队列,探讨 GSD IIIa 患儿的早期肌肉骨骼表现。
我们使用了一系列全面的物理治疗结果测量来横断评估肌肉力量和粗大运动功能,包括改良医学研究委员会(mMRC)量表、握力和侧/关键捏力、粗大运动功能测量(GMFM)、步态、楼梯、Gowers、椅子(GSGC)测试、6 分钟步行测试(6MWT)和布鲁因克斯-奥塞尔斯基运动能力测试第 2 版(BOT-2)。我们还评估了实验室生物标志物(AST、ALT、CK 和尿 Glc4),并对 GSD IIIa 患儿进行了全身磁共振成像(WBMRI)以评估质子密度脂肪分数(PDFF)。在有条件的情况下分析神经传导研究和肌电图结果,并进行了全面的文献回顾。
本研究共评估了 22 名 GSD IIIa 患者,其中 17 名儿科患者和 5 名成年患者。与非疾病同龄人相比,这些儿科患者的 GMFM、6MWT、BOT-2 和 GSGC 测试的手动肌肉测试、握力和侧/关键捏力下降以及功能能力下降。此外,与非疾病同龄人相比,所有分析的实验室生物标志物和 WBMRI 获得的 PDFF 均升高。与儿科队列相比,成年人在功能评估方面的整体表现更差,表明随着年龄的增长,疾病表型的进展。
这些结果表明,GSD IIIa 患儿存在早期肌肉骨骼受累,在物理治疗评估中最为明显,除了更常见的肝脏症状外。儿童和成人的肌肉无力在近端和躯干肌肉以及手部的内在肌肉中最为明显。这些发现表明,早期评估 GSD IIIa 患者以发现肌肉无力并制定针对肝脏和肌肉的治疗方法非常重要。